14,204 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in Cabaletta Bio, Inc. (NASDAQ:CABA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,204 shares of the company’s stock, valued at approximately $67,000.

A number of other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its stake in Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after buying an additional 3,724 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Cabaletta Bio during the third quarter worth about $127,000. SG Americas Securities LLC acquired a new position in shares of Cabaletta Bio in the third quarter worth about $166,000. The Manufacturers Life Insurance Company boosted its stake in Cabaletta Bio by 8.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,424 shares of the company’s stock valued at $422,000 after acquiring an additional 4,191 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Cabaletta Bio by 35.7% in the 2nd quarter. Rhumbline Advisers now owns 61,880 shares of the company’s stock valued at $463,000 after purchasing an additional 16,274 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. UBS Group initiated coverage on Cabaletta Bio in a research note on Thursday, October 10th. They set a “buy” rating and a $10.00 price objective on the stock. Evercore ISI lowered their price target on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Cabaletta Bio in a research note on Friday, November 15th. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Finally, Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, November 15th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $26.25.

Cabaletta Bio Trading Up 1.5 %

CABA stock opened at $3.30 on Monday. The firm has a 50-day moving average of $3.82 and a two-hundred day moving average of $5.88. Cabaletta Bio, Inc. has a one year low of $1.76 and a one year high of $26.35. The firm has a market capitalization of $161.30 million, a PE ratio of -1.53 and a beta of 2.37.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.